JAN 25, 2018 10:00 AM PST

WEBINAR: Engineered Viruses as Precision Cancer Therapeutics

Speaker
  • PhD Researcher
    Biography
      Alex's research is in the nascent field of oncolytic virotherapy, utilizing re-engineered adenoviruses to specifically target and destroy cancer cells. He gained his first degree at the University of Aberdeen in Scotland. Having published research on novel mechanisms of bacterial antibiotic resistance, he joined Absolute Antibody where he developed sophisticated antibody engineering techniques which continue to address a variety of industrial needs. He then returned to Aberdeen to work with Dr Frank Ward on the immune co-checkpoint inhibitor sCTLA-4.
      In 2015, Alex moved to lab of Dr Alan Parker at Cardiff University where he combined his experience of protein engineering and cancer immunology in the development of new virotherapies. He believes that the interdisciplinary approach available in the lab will accelerate the innovative treatments under development there to a translational benefit. As well as his Cardiff based research, Alex maintains an active collaboration with Dr Mitesh Borad at the Mayo Clinic developing next generation antibody therapies for genetically defined cancers.
      Aside from his research responsibilities Alex is passionate about science communication and public engagement. He has run patient engagement days for those with the diseases he works on and organized the first ever Welsh Pint of Science festival to a sold-out audience. Most recently, Alex has been appointed to the board of the British Society of Gene and Cell Therapy (BSGCT) as Early Career Representative where he is responsible for engagement with scientists starting out in the field.

    Abstract

    DATE: January 25, 2018
    TIME: 10:00am PST, 1:00pm EST, 6:00pm GMT

    Oncolytic virotherapy, the use of viral vectors to treat cancer, holds huge promise. Viruses are natural DNA delivery vehicles evolved to target specific tissues and transform them. Oncolytic virotherapies harness these abilities for therapeutic rather than pathological results. By engineering the virus to target cancerous cells rather than healthy cells we can create virotherapies which self-amplify at the point of need. Whilst historically safety focused, the field has now pivoted to enhanced efficacy following the first approved oncolytic virotherapy, T-VEC, for melanoma.

    Our laboratory develops Adenoviruses (Ads) as oncolytics. Ads are versatile platforms offering large transgene capacity, ease of manipulation, and lytic potential with an excellent safety profile. However, current Ad-based therapies are hampered by high levels of pre-existing immunity within the population and off-target effects caused by the promiscuity of Ads’ canonical receptor: CAR.

    We address these issues by a “bottom up” engineering approach to enhance the well characterised Ad5 serotype combined with a “top down” investigation of understudied Adenoviruses with advantageous phenotypes. By engineering Ad5 we can ablate natural tropism and facilitate specific infection of cancer cells; demonstrated by both in vitro, and in vivo models of cancer. Concurrently, we can develop rare Adenovirus serotypes devoid of pre-existing immunity, namely neutralising antibody activity. Integrating proteins from these serotypes into therapeutic vectors enables us to radically improve cancer cell transduction.

    Once targeted, the viruses must be capable of efficient cancer cell killing. We have developed Ad vectors with a variety of transgenes to manipulate signalling pathways for therapeutic benefit. Current research focuses on combining the above aptitudes into a single virus with a 3-pronged therapeutic action:

    • Inherent viral immunogenicity

    • Direct cancer cell lysis

    • Stimulation of anti-tumour immunity

     

    Key Learning Objectives:

    • Understand how protein engineering can be used to generate tissue specific viruses.
    • Learn how re-engineered viruses can be used as cancer therapies.

    Show Resources
    You May Also Like
    MAY 11, 2021 10:00 AM PDT
    C.E. CREDITS
    MAY 11, 2021 10:00 AM PDT
    Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    DEC 02, 2020 8:00 AM PST
    C.E. CREDITS
    DEC 02, 2020 8:00 AM PST
    DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
    APR 01, 2021 8:00 AM PDT
    C.E. CREDITS
    APR 01, 2021 8:00 AM PDT
    Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
    MAR 16, 2021 10:00 AM PDT
    C.E. CREDITS
    MAR 16, 2021 10:00 AM PDT
    Date: March 16, 2021 Time: 10:00am (PST) Scientific progress and breakthroughs today are often too expensive for most institutions to acquire. Each year, the National Institutes of Health (N...
    JAN 25, 2018 10:00 AM PST

    WEBINAR: Engineered Viruses as Precision Cancer Therapeutics


    Specialty

    Cancer Research

    Biotechnology

    Cell Biology

    Immunology

    Molecular Biology

    Cancer Therapeutics

    Cancer Diagnostics

    Cell Culture

    Genetics

    Molecular Diagnostics

    Biomarkers

    Microbiology

    Clinical Research

    Biochemistry

    Clinical Chemistry

    Geography

    North America55%

    Europe23%

    Asia12%

    South America5%

    Africa2%

    Oceania1%

    Registration Source

    Website Visitors86%

    Email Promotions6%

    WAVE Newsletter Promotion6%

    Social Media Promotions1%

    Website Banners1%

    Job Title

    Student19%

    Research Scientist13%

    Medical Laboratory Technician11%

    Scientist9%

    Educator/Faculty8%

    Facility/Department Manager8%

    Executive8%

    Lab Management5%

    Medical Doctor/Specialist5%

    Post Doc4%

    Clinical Laboratory Scientist4%

    Biologist2%

    QC/QA2%

    Microbiologist2%

    Consultant1%

    Chemist1%

    Organization

    Academic Institution15%

    Clinical Laboratory8%

    Biotech Company6%

    Research Institute6%

    Hospital5%

    Life Science Company3%

    Medical School2%

    Ambulatory Care2%

    Pharmaceutical Company2%

    Medical Center2%

    Government2%

    Non-Profit Organization2%

    Industrial Company1%

    Consultant1%

    Other4%


    Show Resources
    Loading Comments...
    Show Resources
    Attendees
    • See more